Linked Life Data

17318859

Source:http://linkedlifedata.com/resource/pubmed/id/17318859

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-3-5
pubmed:abstractText
Hepatitis B vaccination after liver transplantation for hepatitis B-related liver disease has been investigated as an alternative strategy to reinfection prophylaxis with hepatitis B immunoglobulin (HBIG) with conflicting results. In most studies, HBIG treatment was discontinued before vaccination. An outstanding good response was achieved with vaccination under continuous HBIG administration using hepatitis B surface antigen (HBsAg)-based vaccine containing special adjuvants. Both, adjuvants and continuous HBIG administration have been discussed as crucial factors for good response. Twenty-four patients were vaccinated with conventional double dose recombinant vaccine containing 40 microg HBsAg up to 12 times at weeks 0, 2, 4 (cycle 1), 12, 14, 16 (cycle 2), 24, 26, 28 (cycle 3), and 36, 38, 40 (cycle 4). All patients received 2,000 IU HBIG every 6 weeks (4 times intravenously and 4 times intramuscularly). A significant response was defined as reconfirmed increase of anti-HBs-antigen (anti-HBs) unexplained by HBIG administration or lack of anti-HBs decrease below 100 IU/L after discontinuation of HBIG treatment after week 48. Only 2 of 24 patients (8.3%) responded significantly. Anti-HBs started to increase after the seventh vaccination (cycle 3, during intramuscular HBIG administration) in 1 patient and after 12th vaccination (cycle 4, during intravenous HBIG administration) in the other. Maximum anti-HBs levels were >1,000 IU/L in both patients and decreased significantly slower as compared to passive prophylaxis during follow-up. In conclusion, the conventional HBsAg vaccine failed to induce a significant humoral immune response in most patients despite continued HBIG treatment. Further studies should address the question, of whether the use of potent adjuvant systems results in higher response rates.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1527-6465
pubmed:author
pubmed:copyrightInfo
(c) 2007 AASLD.
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
367-73
pubmed:meshHeading
pubmed-meshheading:17318859-Adjuvants, Immunologic, pubmed-meshheading:17318859-Adolescent, pubmed-meshheading:17318859-Adult, pubmed-meshheading:17318859-Aged, pubmed-meshheading:17318859-Antigen-Antibody Complex, pubmed-meshheading:17318859-Dose-Response Relationship, Drug, pubmed-meshheading:17318859-Drug Therapy, Combination, pubmed-meshheading:17318859-Female, pubmed-meshheading:17318859-Hepatitis B, pubmed-meshheading:17318859-Hepatitis B Surface Antigens, pubmed-meshheading:17318859-Hepatitis B Vaccines, pubmed-meshheading:17318859-Humans, pubmed-meshheading:17318859-Immunization, Secondary, pubmed-meshheading:17318859-Immunoglobulins, pubmed-meshheading:17318859-Liver Transplantation, pubmed-meshheading:17318859-Male, pubmed-meshheading:17318859-Middle Aged, pubmed-meshheading:17318859-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation.
pubmed:affiliation
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. Rosenau.jens@mh-hannover.de
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't